Cancer-Killing Virus Shows Promise as Metastatic Cancer Treatment

The virus may be a potential treatment for some metastatic cancers, such as small-cell lung cancer.

Cancer-killing viruses have been shown in clinical trials to be promising therapies for localized cancer. But so far their success has been limited in metastatic cancers. This could be due to the viruses targeting normal cells as well as cancer cells or the viruses being inactivated by a patient's blood or immune system.

Paul Hallenbeck, Ph.D., from Neotropix (Malvern, PA, USA), and colleagues evaluated the cancer-killing potential of the newly discovered Seneca Valley Virus-001 in normal and tumor cell lines. They also assessed the virus in human blood to evaluate whether it would be suitable for intravenous delivery. The researchers examined the safety and effectiveness of the virus in mice engineered with tumors derived from human small-cell lung cancer and childhood eye cancer cell lines.

The Seneca Valley Virus was more effective at killing the lung and eye cancer cell lines than the normal cells, and the virus was not inhibited in the blood. Among mice treated with the virus, there was a complete response in all the mice with lung cancerous tumors and in most of those with eye cancer tumors.

"The data in this report suggest that [the Seneca Valley Virus] may overcome many of the challenges faced by traditional therapies and other [cancer-killing] viruses,” the investigators reported in their study, which was published October 30, 2007 in the Journal of the National Cancer Institute.


Related Links:
Neotropix